首页 > 市场调查报告书 > 医疗设备

药物递输设备包装/容器

市场调查报告书

商品编码

1753028

全球疫苗技术市场

Vaccine Technologies

出版日期: 2025年06月20日 | 出版商:

Global Industry Analysts, Inc. | 英文 573 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球疫苗技术市场规模将达到 805 亿美元

全球疫苗技术市场规模预计在2024年为487亿美元，到2030年将达到805亿美元，在2024-2030年的分析期间内，复合年增长率为8.8%。减毒疫苗是本报告分析的细分市场之一，预计其复合年增长率为7.8%，到分析期结束时规模将达到233亿美元。灭活疫苗细分市场在分析期间的复合年增长率预计为7.9%。

美国市场规模估计为 133 亿美元，中国市场预计复合年增长率为 11.9%

美国疫苗技术市场规模预计2024年达到133亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到160亿美元，在2024-2030年的分析期间内，复合年增长率为11.9%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为6.3%和7.6%。在欧洲，预计德国市场的复合年增长率约为6.8%。

全球「疫苗技术」市场—主要趋势与驱动因素摘要

疫情如何重新定义疫苗创新格局？

COVID-19 疫情是刺激全球投资、创新和合作的关键时刻，以前所未有的方式加速了疫苗技术的演变。在开发和部署有效疫苗的竞赛中，mRNA（辉瑞-BioNTech、Moderna）、病毒载体（Astra Zeneca、强生）和蛋白质次单元等平台的潜力凸显。 mRNA 技术特别表现出高效性和产生快速免疫反应的能力，为 COVID-19 以外的流感、寨兹卡病毒、呼吸道合胞病毒、爱滋病毒甚至癌症免疫治疗的应用打开了大门。这种转变也为生物技术公司和大型製药公司吸引了大量资金，从而建立了可以快速应对新病原体的模组化疫苗平台。包括美国国立卫生研究院和欧洲 EMA 在内的政府机构目前正在与製造商更紧密地合作，以简化核准途径，重点是防范、即时监控和快速反应能力。

新兴市场和低温运输创新发挥什么作用？

非洲、东南亚和拉丁美洲等历史上服务不足的地区正在成为疫苗技术扩展的中心，并对当地製造和分销基础设施进行了战略投资。 COVAX、Gavi 和 CEPI 等全球倡议在实现尖端疫苗的民主化取得和实现技术转移方面发挥关键作用。正在建立区域疫苗生产中心，以减少对进口的依赖，确保在感染疾病时迅速做出反应。同时，超低温冰箱、相变材料和智慧包装等低温运输物流的进步使得 mRNA 製剂等温敏疫苗广泛部署。支援物联网的疫苗库追踪和预测性维护也确保了整个供应链中疫苗的有效性。这些发展正在帮助缩小全球医疗服务的公平差距，并为新兴经济体实施更有效率、可靠和以社区为基础的大规模疫苗接种计划铺平道路。

跨学科合作是否会开拓疫苗开发的新前沿？

随着疫苗技术日益跨学科化，并融合了资料科学、人工智慧和合成生物学，一场重大变革正在发生。人工智慧和机器学习模型通常用于预测抗原标靶、优化mRNA序列和模拟免疫反应，从而加速临床前开发过程。 CRISPR和基因编辑工具正被用于建构下一代疫苗载体，其精度更高、副作用更少。此外，奈米技术正在彻底改变疫苗的递送机制，脂质奈米颗粒和聚合物载体提高了生物有效性、细胞摄取和储存稳定性。联合疫苗、耐热製剂和无针递送系统也正在获得发展动力，因为它们减轻了物流负担并提高了患者的依从性。这些领域的融合不仅使疫苗更有效、更易于获得，而且还为根据个人免疫特征量身定制的个人化疫苗接种策略铺平了道路。这种融合标誌着模式转移，将疫苗定位为精准医疗工具，而非一刀切的解决方案。

是什么推动了疫苗技术市场的快速成长？

疫苗技术市场的成长受到多种因素的驱动，包括技术创新、疾病动态、不断变化的法规和不断变化的消费者期望。新型病原体的出现、抗生素抗药性的上升以及通用感染疾病的重新出现凸显了对强大的疫苗管道和快速生产能力的需求。基于 mRNA、载体和 DNA 的平台的突破性进展缩短了开发时间并提高了可扩展性，使其对感染疾病和非感染疾病应用都具有吸引力。成人疫苗接种曾经主要限于儿童，但现在已被广泛接受，而人口老化、全球旅行和职场要求正在扩大目标人口。疫情过后，民众意识和疫苗素养大幅提高，推动了对常规疫苗和预防性疫苗的需求。监管机构变得更加灵活，透过提供紧急使用途径和加速核准鼓励创新和投资。此外，政府、私人投资者和全球卫生联盟增加的资金使得研发、大规模临床试验和基础设施建设能够加快。这些动力结合在一起，将疫苗技术转变为全球医疗保健领域最具弹性和发展最快的领域之一。

部分

技术（减毒活病毒疫苗、灭活、次单位疫苗、类毒素、病毒载体、传讯RNA）、疾病适应症（感染疾病、非感染疾病）、给药途径（肠外、口服、鼻腔）、目标年龄组（儿童、成人）、分销管道（公共部门、私部门）

受访企业范例（共48家）

AstraZeneca
Bavarian Nordic
Bharat Biotech
BioNTech
CanSino Biologics
CSL Limited（Seqirus）
CureVac
GlaxoSmithKline（GSK）
Inovio Pharmaceuticals
Johnson & Johnson（Janssen）
Medicago
Merck & Co.（MSD）
Moderna
Novavax
Pfizer
Sanofi
Serum Institute of India
Sinopharm
Sinovac Biotech
VBI Vaccines

人工智慧集成

我们正在利用可操作的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

The global market for Vaccine Technologies estimated at US$48.7 Billion in the year 2024, is expected to reach US$80.5 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Live-Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$23.3 Billion by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.3 Billion While China is Forecast to Grow at 11.9% CAGR

The Vaccine Technologies market in the U.S. is estimated at US$13.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.0 Billion by the year 2030 trailing a CAGR of 11.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.3% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR.

Global "Vaccine Technologies" Market - Key Trends & Drivers Summarized

How Has the Pandemic Redefined the Vaccine Innovation Landscape?

The COVID-19 pandemic was a pivotal moment that accelerated the evolution of vaccine technologies in unprecedented ways, catalyzing global investment, innovation, and collaboration. The race to develop and deploy effective vaccines highlighted the potential of platforms like mRNA (Pfizer-BioNTech, Moderna), viral vectors (AstraZeneca, Johnson & Johnson), and protein subunits. These technologies not only proved their efficacy under extreme timelines but also established scalable, adaptable frameworks for combating future infectious diseases. mRNA technology, in particular, demonstrated the ability to generate rapid immune responses with high efficacy, opening doors for its application beyond COVID-19 into areas like influenza, Zika, RSV, HIV, and even cancer immunotherapy. This shift has drawn significant capital into biotech firms and pharmaceutical giants alike, leading to the establishment of modular vaccine platforms that can be quickly tailored for new pathogens. Government agencies, including the U.S. NIH and European EMA, are now working more closely with manufacturers to streamline approval pathways, emphasizing preparedness, real-time surveillance, and rapid-response capabilities.

What Role Are Emerging Markets and Cold Chain Innovations Playing?

Historically underserved regions such as Africa, Southeast Asia, and Latin America are becoming central to the expansion of vaccine technologies, thanks in large part to strategic investments in local manufacturing and distribution infrastructure. Global initiatives like COVAX, Gavi, and CEPI are playing instrumental roles in democratizing access to cutting-edge vaccines and enabling technology transfer. Regional vaccine production hubs are being established to reduce dependency on imports and ensure faster response during outbreaks. At the same time, advancements in cold chain logistics-including ultra-low temperature freezers, phase-change materials, and smart packaging-are enabling broader deployment of temperature-sensitive vaccines such as mRNA formulations. IoT-enabled tracking and predictive maintenance for storage units are also ensuring vaccine potency throughout the supply chain. These developments are helping to bridge the equity gap in global healthcare delivery and are laying the groundwork for mass immunization programs to be implemented more efficiently, reliably, and locally across emerging economies.

Can Cross-disciplinary Integration Unlock New Frontiers in Vaccine Development?

A profound transformation is underway as vaccine technologies become increasingly interdisciplinary, integrating data science, AI, and synthetic biology. AI and machine learning models are now routinely used to predict antigenic targets, optimize mRNA sequences, and simulate immune responses, thereby accelerating the preclinical development process. CRISPR and gene-editing tools are being harnessed to build next-generation vaccine vectors with enhanced precision and reduced side effects. Additionally, nanotechnology is revolutionizing vaccine delivery mechanisms, with lipid nanoparticles and polymer-based carriers improving bioavailability, cellular uptake, and storage stability. Combination vaccines, thermostable formulations, and needle-free delivery systems are also gaining momentum as they reduce logistical burdens and enhance patient compliance. The convergence of these disciplines is not only making vaccines more effective and accessible but also paving the way for personalized immunization strategies tailored to individual immune profiles. This integration represents a paradigm shift that positions vaccines as precision medical tools rather than one-size-fits-all solutions.

What Is Driving the Surging Growth in the Vaccine Technologies Market?

The growth in the vaccine technologies market is driven by several factors that cut across technological innovation, disease dynamics, regulatory evolution, and shifting consumer expectations. The emergence of novel pathogens, rising antimicrobial resistance, and recurring outbreaks of zoonotic diseases have underscored the need for robust vaccine pipelines and rapid production capabilities. Breakthroughs in mRNA, vector-based, and DNA-based platforms have reduced development timelines and enhanced scalability, making them attractive for both infectious and non-infectious disease applications. The widespread acceptance of adult immunization-once limited largely to children-is expanding target demographics, fueled by aging populations, global travel, and workplace mandates. Public awareness and vaccine literacy have surged post-pandemic, increasing demand for both routine and preventive vaccines. Regulatory agencies are becoming more agile, providing accelerated pathways for emergency use and fast-tracked approvals, thereby encouraging innovation and investment. Moreover, increased funding from governments, private investors, and global health alliances is enabling faster R&D, large-scale clinical trials, and infrastructure development. Together, these dynamics are transforming vaccine technologies into one of the most resilient and rapidly advancing sectors in global healthcare.

SCOPE OF STUDY:

The report analyzes the Vaccine Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines, Messenger RNA vaccines); Disease Indication (Infectious Diseases, Non-Infectious Diseases); Administration Route (Parenteral, Oral, Nasal); Age Group (Pediatric, Adult); Distribution Channel (Public Sector, Private Sector)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AstraZeneca
Bavarian Nordic
Bharat Biotech
BioNTech
CanSino Biologics
CSL Limited (Seqirus)
CureVac
GlaxoSmithKline (GSK)
Inovio Pharmaceuticals
Johnson & Johnson (Janssen)
Medicago
Merck & Co. (MSD)
Moderna
Novavax
Pfizer
Sanofi
Serum Institute of India
Sinopharm
Sinovac Biotech
VBI Vaccines

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Vaccine Technologies - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Emergence of mRNA Platforms Spurs Innovation and Market Expansion
- Rising Global Immunization Programs Propel Demand for Advanced Vaccine Technologies
- COVID-19 Pandemic Legacy Strengthens Business Case for Rapid Vaccine Development
- Government and NGO Funding Expands Addressable Market in Low-Income Regions
- Increasing Zoonotic Disease Threats Accelerate R&D in Cross-Species Vaccines
- Personalized and Therapeutic Vaccines Throw the Spotlight on Precision Medicine Applications
- Technological Advancements in Cold Chain Logistics Drive Wider Vaccine Distribution
- DNA, Viral Vector, and Protein Subunit Platforms Generate Opportunities for New Entrants
- Regulatory Fast-Tracking and Emergency Use Authorizations Propel Growth of Novel Vaccines
- Integration of AI and Big Data in Vaccine Discovery Sustains Competitive Innovation Cycles
- Rising Vaccine Hesitancy and Misinformation Pose Public Health and Market Uptake Challenges
- Global Health Security Initiatives Drive Demand for Scalable Vaccine Manufacturing
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Vaccine Technologies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Vaccine Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Live-Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Live-Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Live-Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Toxoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Toxoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Toxoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Viral Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Viral Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Viral Vector Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Messenger RNA vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Messenger RNA vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Messenger RNA vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Nasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 32: World Recent Past, Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 33: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: World 15-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 35: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 36: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 38: World Recent Past, Current & Future Analysis for Public Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 39: World Historic Review for Public Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: World 15-Year Perspective for Public Sector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 41: World Recent Past, Current & Future Analysis for Private Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 42: World Historic Review for Private Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: World 15-Year Perspective for Private Sector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 44: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 45: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 47: World Recent Past, Current & Future Analysis for Non-Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 48: World Historic Review for Non-Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: World 15-Year Perspective for Non-Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 50: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: USA Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: USA 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 53: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: USA Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: USA 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 56: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: USA Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: USA 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 59: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: USA Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: USA 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 62: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: USA Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: USA 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
CANADA
- TABLE 65: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Canada Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Canada 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 68: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Canada Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Canada 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 71: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Canada Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Canada 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 74: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Canada Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Canada 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 77: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Canada Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Canada 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
JAPAN
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 80: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Japan Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Japan 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 83: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Japan Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Japan 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 86: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Japan Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Japan 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 89: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Japan Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Japan 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 92: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Japan Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Japan 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
CHINA
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 95: China Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: China Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: China 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 98: China Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: China Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: China 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 101: China Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: China Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: China 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 104: China Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: China Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: China 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 107: China Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: China Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: China 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
EUROPE
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 110: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 111: Europe Historic Review for Vaccine Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Europe 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 113: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Europe Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Europe 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 116: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: Europe Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: Europe 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 119: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: Europe Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: Europe 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 122: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: Europe Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: Europe 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 125: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Europe Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Europe 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
FRANCE
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 128: France Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: France Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: France 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 131: France Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: France Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: France 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 134: France Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: France Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: France 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 137: France Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: France Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: France 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 140: France Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: France Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: France 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
GERMANY
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 143: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Germany Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Germany 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 146: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Germany Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 148: Germany 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 149: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Germany Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 151: Germany 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 152: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 153: Germany Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 154: Germany 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 155: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Germany Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 157: Germany 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
ITALY
- TABLE 158: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Italy Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 160: Italy 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 161: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: Italy Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 163: Italy 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 164: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Italy Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 166: Italy 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 167: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Italy Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 169: Italy 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 170: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: Italy Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 172: Italy 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
UNITED KINGDOM
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 173: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: UK Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 175: UK 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 176: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: UK Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 178: UK 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 179: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: UK Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 181: UK 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 182: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: UK Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 184: UK 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 185: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: UK Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 187: UK 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
SPAIN
- TABLE 188: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: Spain Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 190: Spain 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 191: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Spain Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 193: Spain 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 194: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Spain Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 196: Spain 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 197: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: Spain Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 199: Spain 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 200: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 201: Spain Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 202: Spain 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
RUSSIA
- TABLE 203: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Russia Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 205: Russia 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 206: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 207: Russia Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 208: Russia 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 209: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 210: Russia Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 211: Russia 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 212: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 213: Russia Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 214: Russia 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 215: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 216: Russia Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 217: Russia 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
REST OF EUROPE
- TABLE 218: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 219: Rest of Europe Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 220: Rest of Europe 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 221: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 222: Rest of Europe Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 223: Rest of Europe 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 224: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 225: Rest of Europe Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 226: Rest of Europe 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 228: Rest of Europe Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 229: Rest of Europe 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 231: Rest of Europe Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 232: Rest of Europe 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
ASIA-PACIFIC
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 233: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 234: Asia-Pacific Historic Review for Vaccine Technologies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 235: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 236: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 237: Asia-Pacific Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 238: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 239: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 240: Asia-Pacific Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 241: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 243: Asia-Pacific Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 244: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 246: Asia-Pacific Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 247: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 249: Asia-Pacific Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 250: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
AUSTRALIA
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 251: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 252: Australia Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 253: Australia 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 254: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 255: Australia Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 256: Australia 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 257: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 258: Australia Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 259: Australia 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 260: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 261: Australia Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 262: Australia 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 263: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 264: Australia Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 265: Australia 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
INDIA
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 266: India Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 267: India Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 268: India 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 269: India Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 270: India Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 271: India 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 272: India Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 273: India Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 274: India 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 275: India Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 276: India Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 277: India 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 278: India Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 279: India Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 280: India 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
SOUTH KOREA
- TABLE 281: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 282: South Korea Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 283: South Korea 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 284: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 285: South Korea Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 286: South Korea 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 287: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 288: South Korea Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 289: South Korea 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 290: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 291: South Korea Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 292: South Korea 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 293: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 294: South Korea Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 295: South Korea 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
- TABLE 296: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 297: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 298: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 299: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 300: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 301: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 302: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 303: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 304: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 306: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 309: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
LATIN AMERICA
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 311: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 312: Latin America Historic Review for Vaccine Technologies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 313: Latin America 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 314: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 315: Latin America Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 316: Latin America 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 317: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 318: Latin America Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 319: Latin America 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 320: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 321: Latin America Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 322: Latin America 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 323: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 324: Latin America Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 325: Latin America 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 326: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 327: Latin America Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 328: Latin America 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
ARGENTINA
- TABLE 329: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 330: Argentina Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 331: Argentina 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 332: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 333: Argentina Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 334: Argentina 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 335: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 336: Argentina Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 337: Argentina 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 338: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 339: Argentina Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 340: Argentina 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 341: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 342: Argentina Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 343: Argentina 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
BRAZIL
- TABLE 344: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 345: Brazil Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 346: Brazil 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 347: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 348: Brazil Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 349: Brazil 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 350: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 351: Brazil Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 352: Brazil 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 353: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 354: Brazil Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 355: Brazil 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 356: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 357: Brazil Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 358: Brazil 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
MEXICO
- TABLE 359: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 360: Mexico Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 361: Mexico 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 362: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 363: Mexico Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 364: Mexico 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 365: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 366: Mexico Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 367: Mexico 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 368: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 369: Mexico Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 370: Mexico 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 371: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 372: Mexico Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 373: Mexico 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
- TABLE 374: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 375: Rest of Latin America Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 376: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 377: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 378: Rest of Latin America Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 379: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 380: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 381: Rest of Latin America Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 382: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 384: Rest of Latin America Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 385: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 387: Rest of Latin America Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 388: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
MIDDLE EAST
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 389: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 390: Middle East Historic Review for Vaccine Technologies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 391: Middle East 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 392: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 393: Middle East Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 394: Middle East 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 395: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 396: Middle East Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 397: Middle East 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 398: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 399: Middle East Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 400: Middle East 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 401: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 402: Middle East Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 403: Middle East 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 404: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 405: Middle East Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 406: Middle East 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
IRAN
- TABLE 407: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 408: Iran Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 409: Iran 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 410: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 411: Iran Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 412: Iran 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 413: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 414: Iran Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 415: Iran 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 416: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 417: Iran Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 418: Iran 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 419: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 420: Iran Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 421: Iran 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
ISRAEL
- TABLE 422: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 423: Israel Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 424: Israel 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 425: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 426: Israel Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 427: Israel 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 428: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 429: Israel Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 430: Israel 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 431: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 432: Israel Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 433: Israel 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 434: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 435: Israel Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 436: Israel 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
SAUDI ARABIA
- TABLE 437: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 438: Saudi Arabia Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 439: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 440: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 441: Saudi Arabia Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 442: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 443: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 444: Saudi Arabia Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 445: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 447: Saudi Arabia Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 448: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 450: Saudi Arabia Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 451: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
- TABLE 452: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 453: UAE Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 454: UAE 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 455: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 456: UAE Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 457: UAE 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 458: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 459: UAE Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 460: UAE 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 461: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 462: UAE Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 463: UAE 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 464: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 465: UAE Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 466: UAE 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
- TABLE 467: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 468: Rest of Middle East Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 469: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 470: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 471: Rest of Middle East Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 472: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 473: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 474: Rest of Middle East Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 475: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 477: Rest of Middle East Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 478: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 480: Rest of Middle East Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 481: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
AFRICA
- Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 482: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 483: Africa Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 484: Africa 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
- TABLE 485: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 486: Africa Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 487: Africa 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
- TABLE 488: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 489: Africa Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 490: Africa 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
- TABLE 491: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 492: Africa Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 493: Africa 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
- TABLE 494: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 495: Africa Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 496: Africa 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030

IV. COMPETITION

02-2729-4219

+886-2-2729-4219

License/价格

全球疫苗技术市场